Sign inJoin waitlistJoin the waitlist

WT

William Tap

Chief, Sarcoma Medical Oncology Service · New York Presbyterian Hospital

Credentials: · · · · ·

History

Sarcoma Medical Oncology Service Division · New York Presbyterian Hospital
Present
New York Presbyterian Hospital
Present

Hematology and Medical Oncology
University of California-Los Angeles
2003–2006
Internal Medicine
Vanderbilt University Medical Center
2000–2003
Sidney Kimmel Medical College at Thomas Jefferson University
1996–2000

Research

Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Nature Genetics · 2019 · 3,156 citations
Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials
The Lancet Oncology · 2018 · 625 citations
Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients
Cell · 2022 · 541 citations

CA
Cristina Antonescu
73 papers
SD
Sandra D'Angelo
63 papers · 27 as a resident
Samuel Singer
59 papers · 3 as a fellow
MD
Mark Dickson
51 papers
Mrinal Gounder
49 papers
PC
Ping Chi
47 papers
MK
Mary Keohan
43 papers
CK
Ciara Kelly
33 papers
Andrew Wagner
32 papers
ER
Evan Rosenbaum
32 papers · 5 as a fellow
Gary Schwartz
29 papers
Sujana Movva
28 papers

Grants

Improving CDK4/6 Inhibition Therapy for Patients with Liposarcoma by Understanding Resistance
National Cancer Institute · R01
Contact PI · $1.5M · Sloan-Kettering Inst Can Research
2025–2030
SPORE in Soft Tissue Sarcoma
National Cancer Institute · P50
Project lead · $614.1K · Sloan-Kettering Inst Can Research
2018–2029

Clinical trials

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Principal investigator · Terminated · Phase 1, Phase 2
National Cancer Institute (NCI)
2015–2022
BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
Principal investigator · Completed · Phase 1, Phase 2
Memorial Sloan Kettering Cancer Center
2014–2019
A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
Principal investigator · Completed · Phase 3
Threshold Pharmaceuticals
2011–2016
Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)
Principal investigator · Terminated · Phase 1, Phase 2
Memorial Sloan Kettering Cancer Center
2011–2015